<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Using population-based data from Sweden, we identified <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) patients (n = 8740) and 5652 monoclonal <z:e sem="disease" ids="C0178650" disease_type="Disease or Syndrome" abbrv="">gammopathy</z:e> of undetermined significance (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e>) patients diagnosed between 1986 and 2005 </plain></SENT>
<SENT sid="1" pm="."><plain>We calculated standardized incidence rates (SIRs) for <z:hpo ids='HP_0000001'>all</z:hpo> subsequent hematologic and <z:e sem="disease" ids="C0935681" disease_type="Neoplastic Process" abbrv="">nonhematologic malignancies</z:e> for MM patients diagnosed before/after 1995 (introduction of high-dose melphalan/autologous stem cell transplantation [HDM-ASCT]) and 2000 (introduction of immunomodulatory drugs [IMiDs]), respectively </plain></SENT>
<SENT sid="2" pm="."><plain>MM patients had an 11.51-fold (95% confidence interval: 8.19-15.74) increased risk of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); risk was very similar before/after 1995 and 2000, respectively </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e> patients had an 8.01-fold (5.40-11.43) increased risk of <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Risk was confined to IgG/IgA, while no IgM <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e> patients developed <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>; patients with monoclonal-protein (M-protein) concentrations &gt; 1.5 g/dL (SIR = 11.12; 3.61-25.96) had higher risk than those &lt; 1.5 g/dL (SIR = 4.67; 1.71-10.16) </plain></SENT>
<SENT sid="5" pm="."><plain>An excess risk of <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancer</z:e> was observed subsequent to both MM (SIR = 2.22; 1.74-2.80) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e> (SIR = 3.30; 2.76-3.90) </plain></SENT>
<SENT sid="6" pm="."><plain>Our novel observations of an excess risk for <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> following IgG/IgA (but not IgM) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e>, and the highest risk associated with M-protein concentrations &gt; 1.5 g/dL, support a role for nontreatment-related factors in <z:e sem="disease" ids="C1136084" disease_type="Neoplastic Process" abbrv="">plasma cell dyscrasias</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> risk following MM was the same before/after the introduction of HDM-ASCT </plain></SENT>
<SENT sid="8" pm="."><plain>Longer follow-up is needed to characterize second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> risks in the IMiD era </plain></SENT>
</text></document>